G
Gary Remington
Researcher at Centre for Addiction and Mental Health
Publications - 538
Citations - 23162
Gary Remington is an academic researcher from Centre for Addiction and Mental Health. The author has contributed to research in topics: Schizophrenia & Antipsychotic. The author has an hindex of 71, co-authored 495 publications receiving 20591 citations. Previous affiliations of Gary Remington include University of Calgary & Mental Health Research Institute.
Papers
More filters
Journal ArticleDOI
Relationship Between Dopamine D2 Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia
TL;DR: The study confirms that D(2) occupancy is an important mediator of response and side effects in antipsychotic treatment, and is consistent with a "target and trigger" hypothesis of antipsychotics action.
Journal ArticleDOI
Serotonin-dopamine interaction and its relevance to schizophrenia
Shitij Kapur,Gary Remington +1 more
TL;DR: Serotonergic modulation of dopaminergic function provides a viable mechanism for enhancing therapeutics in schizophrenia, but much remains unclear.
Journal ArticleDOI
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Guy Chouinard,Barry Jones,Gary Remington,D. Bloom,Donald Addington,G.W. MacEwan,Alain Labelle,Linda Beauclair,Wendy Arnott +8 more
TL;DR: It is suggested that risperidone, at the optimal therapeutic dose of 6 mg/day, produced significant improvement in both positive and negative symptoms without an increase in drug-induced parkinsonian symptoms and with a significant beneficial effect on tardive dyskinesia.
Journal ArticleDOI
Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
TL;DR: Clozapine, at doses known to be effective in routine clinical settings, showed a D 2 occupancy clearly lower than that of typical antipsychotics, while risperidone and olanzapine at their usual clinical doses gave the same level of D2 occupancy as low-dose typical antippsychotics.
Journal ArticleDOI
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.
Oliver D. Howes,Robert A. McCutcheon,Ofer Agid,Andrea de Bartolomeis,Nico J.M. van Beveren,Michael L. Birnbaum,Michael A P Bloomfield,Rodrigo A. Bressan,Robert W. Buchanan,William T. Carpenter,David J. Castle,Leslie Citrome,Zafiris J. Daskalakis,Michael Davidson,Richard J. Drake,Serdar M. Dursun,Bjørn H Ebdrup,Helio Elkis,Peter Falkai,W. Wolfgang Fleischacker,Ary Gadelha,Fiona Gaughran,B. Glenthøj,Ariel Graff-Guerrero,Jaime Eduardo Cecílio Hallak,William G. Honer,James L. Kennedy,Bruce J. Kinon,Stephen M. Lawrie,Jimmy Lee,F. Markus Leweke,James H. MacCabe,Carolyn B. McNabb,Herbert Y. Meltzer,Hans-Jürgen Möller,Shinchiro Nakajima,Christos Pantelis,Tiago Reis Marques,Gary Remington,Susan L. Rossell,Bruce R. Russell,Cynthia Siu,Takefumi Suzuki,Iris E. C. Sommer,David Taylor,Neil Thomas,Alp Üçok,Daniel Umbricht,James T.R. Walters,John M. Kane,Christoph U. Correll +50 more
TL;DR: The authors present consensus guidelines that operationalize criteria for determining and reporting treatment resistance, adequate treatment, and treatment response, providing a benchmark for research and clinical translation in schizophrenia.